The effect of denosumab on kidney function in patients with metastatic breast cancer to bone previously treated with zoledronic acid

被引：1
|
作者：
Purvey, Sneha
Leventakos, Konstantinos
Munjoma, Mutsa S.
Sherman, Michael J.
Desale, Sameer
Herbolshelmer, Pla Maarit
机构：
[1] MedStar Washington Hosp Ctr, Washington, DC USA
[2] MedStar Hlth Res Inst, Washington, DC USA
[3] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e20701
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20701
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
    A. D. Anastasilakis
    S. A. Polyzos
    A. Gkiomisi
    Z. G. Saridakis
    D. Digkas
    I. Bisbinas
    G. T. Sakellariou
    A. Papatheodorou
    P. Kokkoris
    P. Makras
    [J]. Osteoporosis International, 2015, 26 : 2521 - 2527
  • [2] Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
    Anastasilakis, A. D.
    Polyzos, S. A.
    Gkiomisi, A.
    Saridakis, Z. G.
    Digkas, D.
    Bisbinas, I.
    Sakellariou, G. T.
    Papatheodorou, A.
    Kokkoris, P.
    Makras, P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 (10) : 2521 - 2527
  • [3] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    [J]. Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [4] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
  • [5] The Effect of Treatment with Denosumab or Zoledronic Acid on Health Related Quality of Life in Patients with Metastatic Breast Cancer
    Fallowfield, L.
    Patrick, D.
    Body, J. -J
    Lipton, A.
    Tonkin, K. S.
    Qian, Y.
    Zhao, Y.
    Jiang, Q.
    Braun, A.
    Dansey, R.
    Chung, K.
    [J]. CANCER RESEARCH, 2010, 70
  • [6] Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid
    Ito, Tokiko
    Ono, Mayu
    Oba, Takaaki
    Hanamura, Toru
    Kanai, Toshiharu
    Maeno, Kazuma
    Hiraguri, Manabu
    Shingu, Kiyoshi
    Kaneko, Gengo
    Ito, Ken-ichi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [7] IMPAIRMENT OF RENAL FUNCTION IN THE BREAST CANCER PATIENTS WITH BONE METASTASES TREATED WITH ZOLEDRONIC ACID
    Ito, T.
    Shingu, K.
    Kaneko, G.
    Ito, K. -I.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [8] Creatinine clearance in metastatic breast cancer patients treated with zoledronic acid
    Valev, S. S.
    Marinova, V.
    Chavdarova, L.
    Mihaylova, I.
    Miteva, N.
    Timcheva, C.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135
  • [9] Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
    Yanaea, Masashi
    Fujimoto, Shinichiro
    Tane, Kaori
    Tanioka, Maki
    Fujiwara, Kimiko
    Tsubaki, Masanobu
    Yamazoe, Yuzuru
    Morishima, Yoshiyuki
    Chiba, Yasutaka
    Takao, Shintaro
    Komoike, Yoshifumi
    Tsurutani, Junji
    Nakagawa, Kazuhiko
    Nishida, Shozo
    [J]. JOURNAL OF BONE ONCOLOGY, 2017, 8 : 18 - 22
  • [10] Effect of denosumab versus zoledronic acid on health-related quality of life in patients with metastatic breast cancer.
    Fallowfield, L.
    Patrick, D.
    Body, J.
    Lipton, A.
    Tonkin, K. S.
    Qian, Y.
    Jiang, Q.
    Braun, A. H.
    Dansey, R. D.
    Chung, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345